Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats

British Journal of Cancer

Volumn 80, Issue 1-2, 1999, Pages 161-166

  De Wilt, J H W ^a   Manusama, E R ^a   Van Tiel, S T ^a   Van Ijken, M G A ^a   Ten Hagen, T L M ^a   Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Isolated limb perfusion; Melphalan; Rats; TNf

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HYPOXIA; LIMB PERFUSION; MALE; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; RAT; SOFT TISSUE SARCOMA; TEMPERATURE; TOXICITY;

EID: 0032897078     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690335     Document Type: Article

References (41)

1. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T and Rosenberg SA (1998) Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 12: 1479-1489
2. Asher AL, Mule JJ, Reichert CM, Shiloni E and Rosenberg SA (1987) Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963-974
3. Benckhuijsen C, Kroon BBR, Van Geel AN and Wieberdink J (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14: 157-163
4. Borel Rinkes IHM, de Vries MR, Jonker AM, Swaak TJG, Hack CE, Nooijen PTGA, Wiggers T and Eggermont AMM (1997) Isolated hepatic perfusion in the pig with TNF-α with and without melphalan. Br J Cancer 75: 1447-1453
5. Broukaert P, Libert C, Everaerdt B and Fiers W (1992) Selective species specificity of tumor necrosis factor for toxicity in the mouse. Lymphokine Cytokine Res 11: 193-196
6. Clark J, Grabs AJ, Parson PG, Smithers BM, Addison RS and Roberts MS (1994) Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusions of melanoma. Melanoma Res 4: 365-370
7. De Boeck G, van Cauwenberghe K, Eggermont AMM, van Oosterom AT and de Bruijn EA (1997) Determination of melphalan and hydrolysis products in body fluids by GC-MS. J High Res Chromat 20: 697-700
8. De Vries MR, Borel Rinkes IHM, van de Velde CJH, Wiggers T, Tollenaar RAEM, Kuppen PJK, Vahnmeijer A and Eggermont (1998) Isolated hepatic perfusion with tumor necrosis factor-α(TNFα) and melphalan. Rec Results Cancer Res 147: 107-119
9. Eggermont AMM (1996) Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 26: 335-349
10. Eggermont AMM, Schraffordt Koops H. Liénard D, Kroon BBR, van Geel AN, Hoekstra HJ and Lejeune FJ (1996a) Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for non-resectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14: 2653-2665
11. Eggermont AMM, Schraffordt Koops H, Klausner J, Kroon BBR, Schlag PM, Liénard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC and Lejeune FJ (1996b) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg 224: 756-765
12. Engelberts I. Moller A, Schoen GJ, van der Linden CJ and Buurman WA (1991) Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res 10: 69-76
13. Fajardo LF, Kwan HH, Kowalski J, Prionas SD and Allison AC (1992) Dual role of tumor necrosis factor-α in angiogenesis. Am J Pathol 140: 539-544
14. Fraker DL, Alexander HR and Thom AK (1994) Use of tumor necrosis factor in isolated hepatic perfusion. Circ Shock 44: 45-50
15. Fraker DL, Alexander HR, Andrich M and Rosenburg SA (1996) Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 14: 479-489
16. Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T and Thomas JM (1993) Low-dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion. Br J Surg 80: 995-997
17. Klaase JM, Kroon BBR, Benckhuijsen C, van Geel AN, Albus-Lutter CE and Wieberdink J (1989). Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 64: 616-621
18. Klostergaard J, Leroux E, Siddik ZH, Khodadadian M and Tomasovic SP (1992) Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy. Cancer Res 52: 5271-5277
19. Kramer SM and Carver ME (1986) Serum-free in vitro bioassay for the detection of tumor necrosis factor. J Immunol Methods 93: 201-206
20. Krementz ET, Carter RD, Sutherland CM and Hutton I (1977) Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 185: 555-564
21. Kroon BBR, Klaase JM, van Geel AN and Eggermont AMM (1992) Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 4: 223-226
22. Liénard D, Ewalenko P, Delmotte JJ, Renard N and Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60
23. Manusama ER, Nooijen PTGA, Stavast J, Durante NMC, Marquet RL and Eggermont AMM (1996) Synergistic antitumour effect of recombinant human tumour necrosis factor α with melphalan in isolated limb perfusion in the rat. Br J Surg 83: 551-555
24. Niitsu Y, Watanabe, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M and Urushizaki I (1988) Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis. Cancer Res 48: 654-657
25. Nooijen PTGA, Manusama ER, Eggermont AMM, Schalkwijk L, Stavast J, Marquet RL, de Waal RMW and Ruiter DJ (1996a) Synergistic anti-tumour effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathologic, immunohistochemical and electron microscopic study. Br J Cancer 74: 1908-1915
26. Nooijen PTGA, Eggermont AMM, Verbeck MM, Schalkwijk L, Buurman WA, de Waal RMW and Ruiter DJ (1996b) Transient induction of E-selectin expression following TNFalpha-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific. J Immunother Emphasis Tumor Immunol 19: 33-44
27. Omlor G, Gross G, Ecker KW, Burger I and Feifel G (1992) Optimization of isolated hyperthermic limb perfusion. World J Surg 16: 1117-1119
28. Posner M, Liénard D, Lejeune FJ, Rosenfelder D and Kirkwood J (1994) Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor alpha (TNF) alone for metastatic in-transit melanoma. Proc Annu Meet Am Soc Clin Oncol 13: A1351
29. Renard N, Liénard D, Lespagnard L, Eggermont A, Heimann R and Lejeune F (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα). Int J Cancer 57: 656-663
30. Renard N, Nooijen PTGA, Schalkwijk L, de Waal RMW. Eggermont AMM, Liénard D, Kroon BBR, Lejeune FJ and Ruiter DJ (1995) VWF release and platelet aggregation in human melanoma after perfusion with TNFα. J Pathol 176: 279-287
31. Robins HI, d'Oleire F, Kutz M, Bird A, Schmitt-Tiggelaar CL, Cohen JD and Spriggs DR (1995) Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8°C hyperthermia. Cancer Lett 89: 55-62
32. Scheringa M, Keizer A, Jeekel J and Marquet RL (1989) Anti-tumor effect of recombinant TNF-alpha (rMuTNFα) given by continuous i.v. infusion as compared to repeated i.v. injections in a rat metastasis model. Int J Cancer 43: 905-909
33. Scott RN, Kerr DJ, Blackie R, Hughes J, Burnside G, Mackie RM, Byrne DS and McKay AJ (1992) The pharmacokinetic advantages of isolated limb perfusions with melphalan for malignant melanoma. Br J Cancer 66: 159-166
34. Skarsgard LD, Skwarchuk MW, Vinezan A, Kristl J and Chaplin DJ (1995) The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 15: 219-224
35. Thompson JF and Gianoutsos MP (1992) Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16: 227-233
36. Thompson JF, Waugh RC, Saw RPM and Kam PCA (1994) Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 7: 188-192
37. Vaupel P, Kallinowski F and Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic micro environment of human tumors: a review. Cancer Res 49: 6449-6465
38. Vrouenraets BC, Kroon BBR, Ogilvie AC, van Geel AN, Nieweg OE, Swaak AJG and Eggermont AMM (1997) Absence of severe systemic toxicity after leakage controlled isolated limb perfusion (ILP) with high-dose TNFα and melphalan. Melanoma Res 7: s111
39. Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M and Urushizaki I (1988a) Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 48: 650-653
40. Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, Maeda M and Urushizaki (1988b) Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 48: 2179-2183
41. Wu ZY, Smithers BM, Parsons PG and Roberts MS (1997) The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft. Br J Cancer 75: 1160-1166